SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Webhead who wrote (502)3/20/1997 4:24:00 PM
From: Pseudo Biologist   of 1762
 
Ed, thanks for taking the time to dig out all this and for clarifying a number of ambiguous points in my previous posts.

So we know now that
(1) the anti-CD4 molecule is primatized, and therefore not the subject of the PDL agreement.

(2) IDEC has a strong patent position on the "primatization" technology. I was not sure if the patents had been issued or allowed but your post clarifies this now.

(3) the anti-CD20 molecule for non-Hodginks lymphoma (IDEC's most advanced drug) is not humanized (I believe this is a *mouse*-human chimeric, but I am not 100% sure), therefore *not* the subject of the PDL-IDEC announcement either, and thus the press release implies indirectly that IDEC has at least one more *very* promising molecule for which they are willing to pay money to others for the right to continue development without worries of patent infringement, etc.

Thanks again,

Max
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News